Agreed Brett, when looking at predictive models, ask yourself...

Agreed Brett, when looking at predictive models, ask yourself was the model proved on similar data to which you applying it to. Ie. Model was proved on blue chip and commodity markets, does this mean it has similar applicability to speculative markets? In this case perhaps not. In saying that I do appreciate that it was posted as an FYI.

Volume in use is the key, and will be hard given the other players in the market, it well documented that a rep in the OT usually increases use, given they are playing against very big boys in this field it's possible they are still getting drowned out. I'm interested in their. Pricing, one would think they could claim a premium to the market given a reduced rate or no rate of revision on the procedures, with a net benefit to the health system.